At Jacobio, we are developing cancer treatments that have the potential to be first-in-class or best-in-class monotherapies, and core components of innovative combination treatments. We have successfully built up a talented and experienced research and development team, and are interested in collaborations with other complementary organizations. We believe the combination of cumulative capital, diverse product pipeline and local advantages in China, makes us a trusted partner of choice for global biopharmaceutical companies seeking to access the greater China market. We are committed to partnering with entrepreneurs, biotech and pharmaceutical companies around the world to jointly discover and develop innovative products that will bring meaningful cures with unmet medical need. At the moment, Jacobio is seeking for collaborations in the fields shown below:
- Strategic partner for Greater China/Worldwide: highly innovative or globally differentiated projects in oncology or other disease area with unmet medical need.
- Representative fields: targets with “first in class” potential in oncology or other disease with unmet medical need, pioneering technological platforms and projects (such as next generation cell therapy, gene editing, oncolytic virus, application of AI in drug development).
- License-out/co-development of our products.
- Strategic partner for combination therapy with our immunotherapy products.
If you would like additional information on partnering with Jacobio, please contact our business development team at: